Conduct of Stroke-Related Clinical Trials

Stroke: Pathophysiology, Diagnosis, and Management

Volumn , Issue , 2016, Pages 1030-1041

  Pérez, Adriana ^a   Tilley, Barbara C ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018208181     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-29544-4.00063-3     Document Type: Chapter

References (87)

1. Friedman LM, Furberg CD, DeMets DL Fundamentals of clinical trials 2010, Springer, New York.
2. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
4. Brott TG, Hobson RW, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010, 363:11-23.
5. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444-1451.
6. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 2002, 13:120-126.
7. Little KM, Alexander MJ Medical versus surgical therapy for spontaneous intracranial hemorrhage. Neurosurg Clin N Am 2002, 13:339-347.
8. Forster A, Young J, Nixon J, et al. A cluster randomized controlled trial of a structured training programme for caregivers of inpatients after stroke (TRACS). Int J Stroke 2012, 7:94-99.
9. Forster A, Dickerson J, Young J, et al. A structured training programme for caregivers of inpatients after stroke (TRACS): a cluster randomised controlled trial and cost-effectiveness analysis. Lancet 2013, 382:2069-2076.
10. Ginsberg MD, Hill MD, Palesch YY, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke - I: Physiological responses and safety results. Stroke 2006, 37:2100-2106.
11. Garrett-Mayer E The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 2006, 3:57-71.
12. Palesch YY, Tilley BC, Sackett DL, et al. Applying a phase II futility study design to therapeutic stroke trials. Stroke 2005, 36:2410-2414.
13. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006, 66:628-633.
14. Rankin J Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957, 2:200-215.
15. Lees KR, Bath PM, Schellinger PD, et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 2012, 43(4):1163-1170.
16. National Stroke Association The National Stroke Association NIH Stroke Scale (NIHSS) Certification Services 2014, NIH Stroke Scale, Available from, cited 1-29-2014. http://www.stroke.org/site/PageServer?pagename=NIHSS.
17. Tilley BC, Galpern WR Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke 2007, 38(2 Suppl.):800-803.
18. IMS Study Investigators Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004, 35(4):904-911.
19. Khatri P, Hill MD, Palesch YY, et al. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke 2008, 3(2):130-137.
20. Zaidat OO, Lazzaro MA, Gupta R, et al. Interventional Management of Stroke III trial: establishing the foundation. J Neurointerv Surg 2012, 4(4):235-237.
21. Bechhofer RE, Santner TJ, Goldsman DM Design and Analysis of Experiments for Statistical Selection, Screening and Multiple Comparisons 1995, John Wiley & Sons, New York.
22. Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006, 66(5):660-663.
23. Grieve AP, Krams M ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clin Trials 2005, 2(4):340-351.
24. Berry DA Bayesian clinical trials. Nat Rev Drug Discov 2006, 5(1):27-36.
25. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013, 368(10):893-903.
26. Ginsberg MD, Palesch YY, Hill MD, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol 2013, 12(11):1049-1058.
27. Elm JJ, Kamp C, Tilley BC, et al. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord 2007, 22(6):822-827.
28. Campbell MK, Piaggio G, Elbourne DR, et al. Consort 2010 statement: extension to cluster randomised trials. BMJ 2012, 345:e5661.
29. D'Agostino RB, Campbell M, Greenhouse J Non-inferiority trials: continued advancements in concepts and methodology (special papers for the 25th Anniversary of Statistics in Medicine 25(7). Stat Med 2006, 25(7):1097-1099.
30. Karanjia PN, Nelson JJ, Lefkowitz DS, et al. Validation of the ACAS TIA/stroke algorithm. Neurology 1997, 48(2):346-351.
31. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989, 20(7):864-870.
32. Mahoney FI, Barthel DW Functional Evaluation: The Barthel Index. Md State Med J 1965, 14:61-65.
33. Jennett B, Bond M Assessment of outcome after severe brain damage: A Practical Scale. Lancet 1975, 305(7905):480-484.
34. Tilley B, Huang P, O'Brien PC Global Assessment Variables. Wiley Encyclopedia of Clinical Trials 2007, John Wiley & Sons, Inc., New York. R. D'Agostino, L. Sullivan, J. Massaro (Eds.).
35. Hantson L Neurological scales in assessment of stroke. Ischemic Stroke: Recent Advances in Understanding Stroke Therapy 1985, 42-54. International Business Communications, Southborough, MA. J. Grotta, L.P. Miller, A.M. Buchan (Eds.).
36. Lyden PD, Hantson L Assessment scales for the evaluation of stroke patients. J Stroke Cerebrovasc Dis 1998, 7(2):113-127.
37. Grizzle JE A note on stratifying versus complete random assignment in clinical trials. Control Clin Trials 1982, 3(4):365-368.
38. Scott NW, McPherson GC, Ramsay CR, et al. The method of minimization for allocation to clinical trials. A review. Control Clin Trials 2002, 23(6):662-674.
39. Tilley BC, Lyden PD, Brott TG, et al. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol 1997, 54(12):1466-1474.
40. A systems approach to immediate evaluation and management of hyperacute stroke-Experience at eight centers and implications for community practice and patient care. Stroke 1997, 28(8):1530-1540. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
41. Napoles-Springer AM, Grumbach K, Alexander M, et al. Clinical research with older African Americans and Latinos: perspectives from the community. Res Aging 2000, 22(6):668-691.
42. Morisky DE, Green LW, Levine DM Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24(1):67-74.
43. Gillings D, Koch G The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inf J 1991, 25(3):411-424.
44. Hochberg Y A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75(4):800-802.
45. O'Brien PC, Tilley BC, Dyck PJ Composite Endpoints in Clinical Trials. Wiley Encyclopedia of Clinical Trials 2007, John Wiley & Sons, Inc., New York.
46. Tilley BC Contemporary outcome measures in acute stroke research: choice of primary outcome measure and statistical analysis of the primary outcome in acute stroke trials. Stroke 2012, 43(4):935-937.
47. Lu M, Tilley BC Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: data from the NINDS t-PA stroke trial. Stat Med 2001, 20(13):1891-1901.
48. Bath PM, Lees KR, Schellinger PD, et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012, 43(4):1171-1178.
49. Bath PM, Gray LJ, Collier T, et al. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Optimising Analysis of Stroke Trials (OAST) Collaboration. Stroke 2007, 38(6):1911-1915.
50. Savitz SI, Lew R, Bluhmki E, et al. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007, 38(12):3205-3212.
51. McHugh GS, Butcher I, Steyerberg EW, et al. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project. Clin Trials 2010, 7(1):44-57.
52. Saver JL, Gornbein J Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009, 72(15):1310-1315.
53. Scott PA, Meurer WJ, Frederiksen SM, et al. A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial. Lancet Neurol 2013, 12(2):139-148.
54. Koch GG, Davis SM, Anderson RL Methodological advances and plans for improving regulatory success for confirmatory studies. Stat Med 1998, 17(15-16):1675-1690.
55. O'Brien PC The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics 1983, 39(3):787-794.
56. Moye LA Alpha calculus in clinical trials: considerations and commentary for the new millennium. Stat Med 2000, 19(6):767-779.
57. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991, 266(1):93-98.
58. Meade TW, Brennan PJ Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000, 321(7252):13-17.
59. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000, 55(11):1649-1655.
60. Molenberghs G, Kenward MG Missing Data in Clinical Studies 2007, John Wiley & Sons, Ltd., Hoboken, NJ.
61. Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics 2004, 5(3):445-464.
62. Schafer JL Multiple imputation: a primer. Stat Methods Med Res 1999, 8(1):3-15.
63. Taylor JM, Murray S, Hsu CH Survival estimation and testing via multiple imputation. Stat Probab Lett 2002, 58(3):221-232.
64. Li N, Elashoff RM, Li G, et al. Joint modeling of longitudinal ordinal data and competing risks survival times and analysis of the NINDS rt-PA stroke trial. Stat Med 2010, 29(5):546-557.
65. Thompson JMG, Taylor S, Hsu CH Statistical Considerations in the WARSS Collaboration 2002, Presented to American Heart Association Stroke Meeting. San Antonio.
66. Thall PF, Cook JD Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004, 60(3):684-693.
67. U.S.Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research 2010, Guidance for Industry. Adaptive Design Clinical Trials for Drugs and Biologics, Available from, cited 1-31-2014. http://www.fda.gov/downloads/Drugs/%E2%80%A6/Guidances/ucm201790.pdf.
68. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976, 34(6):585-612.
69. O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979, 35(3):549-556.
70. Pocock SJ Group sequential methods in the design and analysis of clinical trials. Biometrika 1977, 64:191-199.
71. Lan KK, Wittes J The B-value: a tool for monitoring data. Biometrics 1988, 44(2):579-585.
72. Elashoff JD NQuery Advisor + nTerim® 2.0 2012, Statistical Solutions Ltd., Boston, MA. http://www.statistical-solutions-software.com/nquery-advisor-nterim/.
73. PASS 13 Power Analysis and Sample Size Software 2013, http://www.ncss.com/software/pass/.
74. Ruiz A, Morillo LE Epidemiologia Clínica, Investigación Clínica aplicada. Tamaño de la Muestra. Programa sistematizado para el calculo del tamaño de la muestra y el poder en diseños de investigación 2001, Panamerican Health Organization/World Health Organization, Bogotá, Colombia, [A computer program to estimate the required sample size and power in clinical research]. V 1.1. Editorial Medica Panamericana. Register at Colombian Government Ministry: Book 13, Volume 7, Item 063. http://paltex.paho.org/bookdetail.asp?bookId=ECR01, A. Pérez, N. Rodríguez, J.F.A. Gil (Eds.).
75. Dupont WD, Plummer WD PS: Power and Sample size Calculation 3.0.43 2011, http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize.
76. The International Cooperative Study of Extracranial/Intracranial Arterial Anastomosis (EC/IC Bypass Study): methodology and entry characteristics. The EC/IC Bypass Study Group. Stroke 1985, 16(3):397-406.
77. Saver JL, Gornbein J Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009, 72(15):1310-1315.
78. Lesaffre E, Scheys I, Frohlich J, et al. Calculation of power and sample size with bounded outcome scores. Stat Med 1993, 12(11):1063-1078.
79. Glass GV Primary, secondary, and meta analysis of research. Educ Res 1976, 5(10):3-8.
80. Cochrane Handbook for Systematic Reviews of Interventions 2008, The Cochrane Collaboration, Version 5.0.1; Available from, cited 1-10-2014. http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
81. Wardlaw JM, Warlow CP, Counsell C Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997, 350(9078):607-614.
82. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008, 39(6):1751-1758.
83. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis. Int J Stroke 2013, 8(4):278-283. Stroke Thrombolysis Trialists' Collaborative Group.
84. Emberson J, Lees KR, Lyden P, et al. Impact of treatment delay, age and stroke severity on the effects of intravenous thrombolysis with alteplase in acute ischaemic stroke: an individual patient data meta-analysis of randomised trials. Lancet 2015, 2014.
85. International Conference of Harmonisation Guidance for Industry. E6. Good Clinical Practice: Consolidated Guidance 1996, U.S. Food and Drug Administration. U.S.Department of Health and Human Services, Available from, cited 1-24-2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf.
86. U.S.Department of Health and Human Services Food and Drug Administration. Office of Good Clinical Practice. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Center for Devices and Radiological Health. Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors. Exception from Informed Consent Requirements for Emergency Research 2013, Available from, cited 1-31-2014. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm249673.pdf.
87. Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997, 28(11):2119-2125. The NINDS t-PA StrokeStudy Group.